Dormant leukemia refers to leukemia cells that have entered a state of deep biological inactivity, essentially hitting pause on their own growth while sheltering inside the body. These cells are alive but not dividing, which makes them invisible to most standard treatments and, in many cases, to routine blood tests. And yes, they can wake up. Relapses have been documented more than twenty years after a patient’s initial remission, which tells us that dormant leukemia cells can persist for remarkably long stretches before something triggers them back into action.
What Dormancy Actually Means in Leukemia
The word “dormant” gets thrown around casually, but in leukemia biology it describes something specific: quiescence. A quiescent cell has stepped out of the cycle of growth and division. It is not dead, not damaged, and not senescent (permanently retired). It is sitting quietly, consuming very little energy, and waiting. Normal blood-forming stem cells in your bone marrow do this all the time. They spend most of their lives in quiescence, waking up only occasionally to produce fresh blood cells.1PubMed. Quiescence regulation by normal haematopoietic stem cells and leukaemia stem cells Leukemia stem cells hijack the same program, borrowing the normal stem cell’s trick of lying low to protect themselves from damage and, critically, from drugs designed to kill rapidly dividing cells.
This is not a rare fringe behavior. Researchers now consider leukemia stem cell quiescence a central mechanism behind treatment resistance and relapse. The cells that survive a round of intensive chemotherapy are often the ones that were not dividing when the drugs arrived.2PubMed Central. Targeting leukemic stem cells by breaking their dormancy Because most chemotherapy agents work by disrupting the machinery of cell division, a cell that is not dividing can ride out the storm largely unharmed.
Where Dormant Cells Hide
Leukemia stem cells do not just go quiet on their own. They rely on a physical sanctuary: the bone marrow microenvironment, often called the niche. This is the same sheltered zone that houses normal blood stem cells. The niche is made up of various support cells, including mesenchymal stromal cells, along with signaling molecules and structural proteins that together create a protective cocoon. Key molecular signals from the niche, such as CXCL-12 and Jagged-1, help anchor stem cells in place and maintain their quiescent state.3Nature Communications. Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance Leukemia stem cells essentially exploit this protective housing, settling into the same neighborhood that normal stem cells use and receiving many of the same survival signals.
Research has also shown that the niche changes with age. In younger bone marrow, the support cells express higher levels of CXCL-12 and Jagged-1, which translates to stronger self-renewal signals for stem cells.4Scientific Reports. Age-related differences in the bone marrow stem cell niche generate specialized microenvironments for the distinct regulation of normal hematopoietic and leukemia stem cells This does not mean leukemia is more “dormant” in children, but it does suggest that the microenvironment’s specific character shapes how stem cells, whether healthy or malignant, behave at different life stages.
The Molecular Locks That Keep Leukemia Asleep
Quiescence is not simply the absence of growth signals. It is actively maintained by a network of molecular controls. Recent work has zeroed in on changes at the level of chromatin, the packaging system that determines which genes a cell can read and which stay sealed off. In leukemia stem cells, a network of transcription factors centered on a protein called JUN plays a critical role. JUN activity is both necessary and sufficient to hold leukemia stem cells in their quiescent state, and its presence is associated with chemotherapy resistance across diverse patients.3Nature Communications. Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance In plain terms, these cells have a specific gene-reading program turned on that keeps them parked. Disrupting that program could theoretically force them out of dormancy and into vulnerability.
The metabolic profile of dormant leukemia stem cells is also distinctive. Compared to the actively dividing bulk of leukemia cells, quiescent leukemia stem cells run on very low energy. They show reduced rates of oxidative metabolism and lower glycolysis. Even when researchers experimentally blocked their mitochondrial energy production to force the cells onto the backup glycolytic pathway, the dormant cells had a strikingly poor ability to ramp up glycolysis to compensate.5Cell Stem Cell. BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells This metabolic sluggishness is part of what makes them hard to kill, but it also represents a potential Achilles’ heel, which we will come back to.
How Dormant Leukemia Wakes Up
The short answer is that we do not fully understand all the triggers, but the phenomenon is well documented. Case reports describe leukemia recurring more than a decade after treatment, including cases of childhood acute lymphoblastic leukemia relapsing over twenty years after initial remission and chronic myeloid leukemia returning thirteen to seventeen years after a bone marrow transplant.6Leukemia Research / Elsevier. Very late recurrences of leukemia: why does leukemia awake after many years of dormancy? These very late relapses strongly suggest that at least some leukemia cells persisted in a dormant state for the entire intervening period, then something tipped them back into active growth.
Several candidate mechanisms have been proposed. One involves changes in the bone marrow niche itself: as you age, your microenvironment shifts, and signals that once kept cells anchored in quiescence may weaken or change. Immune surveillance is another factor. A healthy immune system can keep dormant cancer cells in check, at least in part because the sheer physical distance between rare dormant cells and patrolling immune cells makes contact unlikely.7PubMed Central. Immune evasion by dormant disseminated cancer cells: A Fermi paradox? If your immune function declines due to aging, illness, or immunosuppressive medication, that low-probability contact becomes even less likely, giving dormant cells more room to eventually re-enter the cell cycle without interference.
There is also evidence that dormant leukemia cells are not genetically frozen in time. Research comparing different cancer types found that while some dormant cancers maintain genetic stability during their quiet period, dormant leukemia cells can accumulate mutations even while not actively dividing.8Cancer Cell Management. Cancer cell dormancy: An update to 2025 This ongoing genetic evolution means that by the time a dormant leukemia cell wakes up, it may have acquired new mutations that make it more aggressive or resistant to the drugs that worked the first time.
External Stressors and Reactivation
Can life circumstances influence whether dormant leukemia cells reactivate? This is an area of active research, and the evidence is preliminary but thought-provoking. In mouse models of acute lymphoblastic leukemia, chronic stress significantly increased tumor burden. Animals subjected to prolonged restraint stress showed roughly double the leukemia cell growth compared to unstressed controls by the two-week mark, an effect mediated through beta-adrenergic signaling, the same pathway activated by your fight-or-flight stress hormones.9PubMed Central. Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling This does not mean stress “causes” leukemia relapse in humans, but it does suggest that stress-related hormones can create a more permissive environment for leukemia cells to grow.
Circadian rhythm disruption is another intriguing factor. The core circadian clock genes, CLOCK and BMAL1, turn out to be required for leukemia stem cell function in acute myeloid leukemia. Disrupting these clock components in lab settings produced anti-leukemic effects, including impaired growth and depletion of leukemia stem cells. Interestingly, while both normal blood stem cells and leukemia stem cells maintain functioning internal clocks with robust daily oscillations, leukemia cells appear specifically dependent on the circadian pathway in ways that normal cells are not.10PubMed Central. Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML The practical implications of this are still being worked out, but it raises the possibility that chronic circadian disruption, from shift work, prolonged sleep loss, or jet lag, could influence how leukemia stem cells behave.
Pre-Leukemic Stem Cells and the Long Runway to Disease
Dormancy in leukemia is not limited to cells that remain after treatment. There is a related phenomenon that happens before anyone is ever diagnosed. Some people carry what are called pre-leukemic stem cells: blood-forming stem cells that have picked up one or a few mutations associated with leukemia but have not yet progressed to full-blown disease. These cells look normal on routine tests and produce functional blood cells, but they carry founding mutations that, if additional hits accumulate over time, can tip them into overt leukemia.
Genomic analysis of bone marrow from patients newly diagnosed with acute myeloid leukemia has revealed that the mutations present in their leukemia cells were already present in what appeared to be otherwise normal stem cells. Researchers have traced this clonal evolution, showing that mutations accumulate stepwise in self-renewing stem cells, with pre-leukemic clones potentially sitting quietly for years before acquiring the final mutations that trigger full disease.11PubMed Central. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia This finding also helps explain relapse: even if chemotherapy wipes out the leukemia, the pre-leukemic stem cells that spawned it may survive, carrying their founding mutations, and eventually give rise to a new round of disease.
How Doctors Look for Dormant Leukemia
You cannot see dormant leukemia cells on a standard blood count. They exist in tiny numbers, tucked away in the bone marrow, and detecting them requires specialized techniques collectively known as measurable residual disease (MRD) testing. The goal of MRD testing is to find the one-in-a-hundred-thousand (or even one-in-a-million) leukemia cells hiding among normal marrow cells after treatment.
The two main MRD approaches are flow cytometry and molecular testing. Advanced flow cytometry panels can now simultaneously measure dozens of surface markers on individual cells, hunting for the telltale abnormal protein combinations that mark leukemia cells. A recently developed 29-color single-tube assay, for example, can simultaneously detect residual disease and evaluate leukemia stem cells, achieving sensitivity well below 0.1%.12PubMed. Development of a 29-Color Single-Tube Full Spectrum Flow Cytometry Assay for the Detection of Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia Molecular techniques based on PCR or next-generation sequencing can push sensitivity even further, potentially detecting one abnormal cell among 100,000 normal ones, though achieving maximum reliability requires processing large numbers of cells, ideally five million or more.13BoletÃn médico del Hospital Infantil de México. Molecular and cellular markers for measurable residual disease in acute lymphoblastic leukemia
MRD testing has become a standard part of leukemia care because it is one of the strongest predictors of relapse. A patient who tests MRD-negative after treatment has a much better prognosis than one who still has detectable residual cells. But a negative MRD result does not guarantee zero dormant cells. It means the remaining cells, if any, are below the detection threshold. Given that dormant leukemia stem cells can hide for decades, even the most sensitive MRD test cannot rule out their presence entirely.
Treatment Strategies Aimed at Dormant Cells
The uncomfortable reality is that conventional chemotherapy largely misses dormant leukemia stem cells. This has pushed researchers toward several creative strategies, broadly grouped into two camps: wake them up and kill them, or target them while they sleep.
The “wake them up” approach tries to coax dormant cells out of quiescence and back into the cell cycle, where conventional drugs can reach them. One line of investigation focuses on CXCR4 antagonists, drugs that interfere with the molecular anchor (CXCL-12/CXCR4 signaling) keeping leukemia stem cells lodged in the protective bone marrow niche. By blocking this interaction, the hope is to flush dormant cells out of their shelter and make them vulnerable.14Elsevier / Experimental Hematology. In and out of the niche: perspectives in mobilization of hematopoietic stem cells Some of these agents are already used clinically to mobilize normal stem cells for transplant, so repurposing them for leukemia stem cell mobilization is an active area of investigation.
The “kill them in their sleep” approach is arguably further along. The metabolic vulnerability described earlier, where dormant leukemia stem cells rely heavily on a specific form of energy production, has been exploited with drugs like venetoclax, a BCL-2 inhibitor. BCL-2 is an anti-death protein that dormant leukemia stem cells depend on for survival. Blocking it can selectively eradicate these quiescent cells.5Cell Stem Cell. BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells Venetoclax has already transformed treatment of acute myeloid leukemia in older adults and is now being tested in combinations designed to further enhance its ability to eliminate leukemia stem cells. One promising combination pairs venetoclax with a PPARα activator called chiglitazar, which in preclinical models synergistically killed leukemia stem-like cells and suppressed disease progression in mice carrying patient-derived tumors, while sparing normal cells.15Cell Death & Disease. Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia
A third angle involves modifying existing drugs or their delivery to better penetrate the bone marrow niche where dormant cells reside. Enhanced drug-delivery vehicles and cell-cycle-modulating agents are both being explored, though most remain in early-stage research.16PubMed. Targeting dormant tumor cells to prevent cancer recurrence The overarching theme is the same: standard chemotherapy was designed for a fast-growing enemy, and dormant leukemia is a slow, patient adversary that demands different tools.
Signals From the Surrounding Cells
The bone marrow niche does not just passively shelter dormant leukemia cells. It actively communicates with them. One channel of communication that has attracted recent attention involves exosomes, tiny membrane-bound packages that cells release to shuttle proteins, genetic material, and signaling molecules to their neighbors. Exosomes released by bone marrow mesenchymal stromal cells can suppress leukemia cell proliferation and cell-cycle progression in lab settings, while increasing markers of cell death. Treated leukemia cells showed increased levels of tumor-suppressing proteins like p53 and BAX and decreased levels of survival proteins like BCL-2.17PubMed Central. The effect of bone marrow mesenchymal stromal cell exosomes on acute myeloid leukemia’s biological functions: a focus on the potential role of LncRNAs
This cuts in an interesting direction. The niche appears capable of both protecting leukemia stem cells through anchoring signals and suppressing their growth through exosome cargo. Which signal dominates likely depends on the specific context: the type of leukemia, the composition of the niche, the patient’s age, and probably factors we have not identified yet. The interplay is not a simple on-off switch but more like a tug of war, with the dormant leukemia cell sitting in the middle, receiving conflicting instructions from its environment.
What Patients and Families Should Know
If you or someone you care about has been treated for leukemia and achieved remission, the concept of dormant leukemia cells understandably raises anxiety. A few practical points are worth keeping in mind. First, remission is still the goal and remains meaningful. The vast majority of patients who achieve deep remission, especially those who test MRD-negative, do well long term. Dormant cells are a real biological phenomenon, but they do not make relapse inevitable.
Second, the timeline for risk changes with leukemia type. In acute lymphoblastic leukemia, most relapses happen within the first few years, though very late relapses beyond a decade do occur. In chronic myeloid leukemia treated with tyrosine kinase inhibitors, some patients can discontinue therapy and remain in remission, while others will see the disease return, usually within the first year of stopping. MRD monitoring helps guide these decisions. Ask your oncologist what monitoring schedule makes sense for your situation and how MRD results are being used to adjust your treatment plan.
Third, the research into targeting dormant leukemia stem cells is moving quickly. Drugs like venetoclax that specifically exploit the vulnerabilities of quiescent cells are already in clinical use, and combination strategies are being tested in trials. The science has moved well past the stage of simply describing the problem and into actively developing countermeasures. That trajectory, from understanding dormancy’s biology to designing drugs that circumvent it, represents one of the more promising directions in leukemia research over the past decade.
The Body’s Internal Clock and Leukemia Stem Cells
One of the more unexpected findings in this field is that leukemia stem cells have a functional circadian clock, and they depend on it. The circadian transcription factors CLOCK and BMAL1, which regulate daily biological rhythms in virtually every cell in the body, turn out to be required for leukemia stem cell maintenance. When researchers knocked out these clock genes, leukemia cells lost their ability to proliferate efficiently, began differentiating into more mature (and less dangerous) cells, and the leukemia stem cell pool shrank.10PubMed Central. Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML Normal blood stem cells also have internal clocks, but they did not show the same dependence, meaning the circadian pathway might offer yet another selective vulnerability in leukemia stem cells.
What makes this finding tantalizing is its potential clinical relevance. Chronotherapy, the idea of timing drug administration to align with the body’s circadian rhythms, has been explored in oncology for years with mixed results. If leukemia stem cells are uniquely dependent on clock genes, there may be an optimal time of day to deliver certain drugs, or clock-disrupting agents might one day be added to treatment regimens. None of this is ready for the clinic yet, but it adds another dimension to the picture: dormant leukemia is not just about whether cells are dividing. It is about when they are most vulnerable, what signals they are listening to, and what rhythms they are keeping, even in their sleep.